Uganda Introduces Cabotegravir for HIV Prevention

Spread the love by sharing

The Ministry of Health Uganda has announced that it is set to introduce a new long-acting injectable for HIV prevention, cabotegravir (CAB-LA), beginning this September.

Cabotegravir tablets and cabotegravir extended-release injectable suspension (also known as long-acting injectable cabotegravir) can be used for pre-exposure prophylaxis (PrEP) to reduce the risk of getting HIV in people who are HIV negative.

According to the World Health Organization, which recommended the use of the drug as early as 2012, CAB-LA is an intramuscular injectable, long-acting form of PrEP, with the first 2 injections administered 4 weeks apart, followed thereafter by an injection every 8 weeks.

Also Read: BREAKING: One Suspected Mpox case registered in Moyo

CAB-LA was shown to be safe and highly effective among cisgender women, cisgender men who have sex with men, and transgender women who have sex with men in two randomized controlled trials, HPTN 083 and HPTN 084.

Together, these landmark studies found that the use of CAB-LA resulted in a 79% relative reduction in HIV risk compared with oral PrEP, where adherence to taking daily oral medication was often a challenge.

Long-acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences.

Check also;

written by @enock katamba

Administrator

Mr. katamba Enock: Professional designer with experience in web designing who started this activity in 2019 at Kyambogo University after graduation . Contact me on : (+256-758287080)